Angioimmunoblastic T-cell lymphoma laboratory tests: Difference between revisions

	Angioimmunoblastic T-cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Angioimmunoblastic T-cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
MRI
Biopsy
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Angioimmunoblastic T-cell lymphoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Angioimmunoblastic T-cell lymphoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Angioimmunoblastic T-cell lymphoma laboratory tests
CDC on Angioimmunoblastic T-cell lymphoma laboratory tests
Angioimmunoblastic T-cell lymphoma laboratory tests in the news
Blogs on Angioimmunoblastic T-cell lymphoma laboratory tests
Directions to Hospitals Treating Angioimmunoblastic T-cell lymphoma
Risk calculators and risk factors for Angioimmunoblastic T-cell lymphoma laboratory tests

Revision as of 20:26, 28 December 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Laboratory tests for angioimmunoblastic T-cell lymphoma include complete blood count (CBC), polyclonal hypergammaglobulinemia, FISH, blood chemistry studies, flow cytometry, immunohistochemistry, and immunophenotyping.^[1]

Laboratory tests for angioimmunoblastic T-cell lymphoma include:^[1]

↑ ^1.0 ^1.1 Angioimmunoblastic T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd52dc/ Accessed on November 27, 2015

@@ Line 17: / Line 17: @@
 :* Negative for the Epstein-Barr virus ([[EBV]])
 * Immunophenotyping
-:* Positivity for [[CD2]], [[CD3]], [[CD4]], [[CD5]], [[CD10]], [[CD20]] and focal positivity for [[CXCL13]]
+:* Positivity for [[CD2]], [[CD3]], [[CD4]], [[CD5]], [[CD10]], [[CD20]], and focal positivity for [[CXCL13]]
 :* Negative for ALK1 and [[CD30]]
 ==References==